This cluster groups 3 independently calculated changes: Revenue increased 466.4%; Operating margin moved 62050 bp higher; Operating income increased 10.6%.
3 evidence-backed components· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTKymera Therapeutics, Inc.'s latest supported as-filed period reports revenue of $0, 466.4% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 466.4%; Operating margin moved 62050 bp higher; Operating income increased 10.6%.
3 evidence-backed componentsCurrent assets changed +89.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
KYMR · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-436975SEC ↗8-KOct 29, 2026Period Oct 29, 20260001193125-26-436965SEC ↗4Oct 1, 2026Period Oct 1, 20260001193125-26-410839SEC ↗4Sep 4, 2026Period Sep 4, 20260001193125-26-383874SEC ↗10-QAug 5, 2026Period Jun 30, 20260001193125-26-333849SEC ↗8-KAug 5, 2026Period Aug 5, 20260001193125-26-333834SEC ↗4Jul 27, 2026Period Jul 27, 20260001193125-26-318408SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 1, 2026Filed Oct 1, 2026 | Mainolfi NelloChief Executive Officer | Option ExerciseDirect | 30,000 | $0 | $0 | Form 4 ↗ |
| Oct 1, 2026Filed Oct 1, 2026 | Mainolfi NelloChief Executive Officer | Open Market SaleDirect | 5,506 | $112 | $618,985 | Form 4 ↗ |
| Oct 1, 2026Filed Oct 1, 2026 | Mainolfi NelloChief Executive Officer | Open Market SaleDirect | 4,876 | $113 | $552,158 | Form 4 ↗ |
| Oct 1, 2026Filed Oct 1, 2026 | Mainolfi NelloChief Executive Officer | Open Market SaleDirect | 7,601 | $114 | $869,782 | Form 4 ↗ |
| Oct 1, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Working capital / assets changed -1618 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital changed +99.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating margin changed +62050 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Revenue changed +466.4% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Revenue changed -100.0% from the comparable as-filed period.
Cash & equivalents changed -62.9% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-09-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-318078| Mainolfi NelloChief Executive Officer |
| Open Market SaleDirect |
| 8,230 |
| $115 |
| $949,742 |
| Form 4 ↗ |
| Oct 1, 2026Filed Oct 1, 2026 | Mainolfi NelloChief Executive Officer | Open Market SaleDirect | 262 | $116 | $30,423 | Form 4 ↗ |
| Oct 1, 2026Filed Oct 1, 2026 | Mainolfi NelloChief Executive Officer | Option ExerciseDirect | 30,000 | $2 | $62,400 | Form 4 ↗ |
| Oct 1, 2026Filed Oct 1, 2026 | Mainolfi NelloChief Executive Officer | Open Market SaleDirect | 3,525 | $111 | $392,826 | Form 4 ↗ |
| Sep 4, 2026Filed Sep 4, 2026 | Adams BrianChief Legal Officer | Open Market SaleDirect | 1,209 | $116 | $139,700 | Form 4 ↗ |
| Sep 4, 2026Filed Sep 4, 2026 | Adams BrianChief Legal Officer | Open Market SaleDirect | 3,025 | $117 | $353,350 | Form 4 ↗ |
| Sep 4, 2026Filed Sep 4, 2026 | Adams BrianChief Legal Officer | Open Market SaleDirect | 2,137 | $118 | $251,247 | Form 4 ↗ |
| Jul 27, 2026Filed Jul 27, 2026 | Rooney TerenceChief Medical Officer | Grant Or AwardDirect | 76,000 | $0 | $0 | Form 4 ↗ |
| Jul 27, 2026Filed Jul 27, 2026 | Rooney TerenceChief Medical Officer | Grant Or AwardDirect | 38,000 | $0 | $0 | Form 4 ↗ |